[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cellectar Biosciences Inc (CLRB)

Cellectar Biosciences Inc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,441
  • Shares Outstanding, K 4,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,790 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 1
  • High Estimate $-0.47
  • Low Estimate $-0.47
  • Prior Year $-3.39
  • Growth Rate Est. (year over year) +86.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +26.29%
on 04/29/26
4.70 -32.55%
on 05/05/26
+0.33 (+11.62%)
since 04/21/26
3-Month
2.43 +30.45%
on 04/01/26
4.70 -32.55%
on 05/05/26
-0.21 (-6.21%)
since 02/20/26
52-Week
2.43 +30.45%
on 04/01/26
20.60 -84.61%
on 06/04/25
-4.30 (-57.56%)
since 05/21/25

Most Recent Stories

More News
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)  Completed Financing of up to $140 Million to Support Initiation of...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management,...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Expands Global Intellectual Property Estate

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.17 (unch)
CLRBW : 0.13 (+348.28%)

Business Summary

Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in...

See More

Key Turning Points

3rd Resistance Point 3.47
2nd Resistance Point 3.33
1st Resistance Point 3.25
Last Price 3.17
1st Support Level 3.03
2nd Support Level 2.89
3rd Support Level 2.81

See More

52-Week High 20.60
Fibonacci 61.8% 13.66
Fibonacci 50% 11.51
Fibonacci 38.2% 9.37
Last Price 3.17
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.